EHS
EHS

More Chemo Switching Suggested for PDAC

Switching chemotherapy in patients with borderline or locally advanced pancreatic ductal adenocarcinoma improved outcomes in a retrospective study conducted at Mayo Clinic. Patients who did not respond to first-line therapy had substitutions that ultimately were beneficial to a majority, according to the researchers.
EHS
Back to top button